Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats.

Guan SJ, Ma ZH, Wu YL, Zhang JP, Liang F, Weiss JW, Guo QY, Wang JY, Ji ES, Chu L.

Food Chem Toxicol. 2012 Jun;50(6):1874-82. doi: 10.1016/j.fct.2012.03.006. Epub 2012 Mar 10.

PMID:
22429817
2.

Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension.

Waddingham MT, Edgley AJ, Astolfo A, Inagaki T, Fujii Y, Du CK, Zhan DY, Tsuchimochi H, Yagi N, Kelly DJ, Shirai M, Pearson JT.

Cardiovasc Diabetol. 2015 Jul 22;14:92. doi: 10.1186/s12933-015-0256-6.

4.

Preventive effects of fasudil on adriamycin-induced cardiomyopathy: possible involvement of inhibition of RhoA/ROCK pathway.

Wang N, Guan P, Zhang JP, Chang YZ, Gu LJ, Hao FK, Shi ZH, Wang FY, Chu L.

Food Chem Toxicol. 2011 Nov;49(11):2975-82. doi: 10.1016/j.fct.2011.06.080. Epub 2011 Jul 22.

PMID:
21803115
5.

Rho-Kinase inhibitor fasudil suppresses high glucose-induced H9c2 cell apoptosis through activation of autophagy.

Gao H, Hou F, Dong R, Wang Z, Zhao C, Tang W, Wu Y.

Cardiovasc Ther. 2016 Oct;34(5):352-9. doi: 10.1111/1755-5922.12206.

PMID:
27333569
6.

Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats.

Li WJ, Park K, Paick JS, Kim SW.

J Sex Med. 2011 Feb;8(2):400-10. doi: 10.1111/j.1743-6109.2010.01724.x.

PMID:
20233282
7.

Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.

Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, Shimokawa H, Hafezi-Moghadam A, Ishibashi T.

Diabetes. 2009 Jan;58(1):215-26. doi: 10.2337/db08-0762. Epub 2008 Oct 7.

8.

Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproterenol-induced heart failure in rats via JNK and ERK1/2 pathways.

Wang N, Guan P, Zhang JP, Li YQ, Chang YZ, Shi ZH, Wang FY, Chu L.

J Cell Biochem. 2011 Jul;112(7):1920-9. doi: 10.1002/jcb.23112.

PMID:
21433064
9.

Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.

Pearson JT, Jenkins MJ, Edgley AJ, Sonobe T, Joshi M, Waddingham MT, Fujii Y, Schwenke DO, Tsuchimochi H, Yoshimoto M, Umetani K, Kelly DJ, Shirai M.

Cardiovasc Diabetol. 2013 Aug 1;12:111. doi: 10.1186/1475-2840-12-111.

10.

Hydroxyl fasudil, an inhibitor of Rho signaling, improves erectile function in diabetic rats: a role for neuronal ROCK.

Sezen SF, Lagoda G, Musicki B, Burnett AL.

J Sex Med. 2014 Sep;11(9):2164-71. doi: 10.1111/jsm.12613. Epub 2014 Jun 12.

11.

The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells.

Kanazawa Y, Takahashi-Fujigasaki J, Ishizawa S, Takabayashi N, Ishibashi K, Matoba K, Kawanami D, Yokota T, Tajima N, Utsunomiya K.

Exp Neurol. 2013 Sep;247:438-46. doi: 10.1016/j.expneurol.2013.01.012. Epub 2013 Jan 18.

PMID:
23337773
12.

Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats.

Ma Z, Zhang J, Ji E, Cao G, Li G, Chu L.

Clin Exp Pharmacol Physiol. 2011 Oct;38(10):688-94. doi: 10.1111/j.1440-1681.2011.05561.x.

PMID:
21711379
13.

The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats.

Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, Kurata H, Tajima N.

Eur J Pharmacol. 2007 Jul 30;568(1-3):242-7. Epub 2007 Apr 20.

PMID:
17511984
14.

A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.

Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, Miura S.

J Endocrinol. 2007 Mar;192(3):595-603.

15.

Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes.

Zhou H, Fang C, Zhang L, Deng Y, Wang M, Meng F.

Chin Med J (Engl). 2014;127(2):225-31.

PMID:
24438608
16.

Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage.

Abdali NT, Yaseen AH, Said E, Ibrahim TM.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Apr;390(4):409-422. doi: 10.1007/s00210-017-1343-x. Epub 2017 Jan 18.

PMID:
28101628
17.

The influence of fasudil on the epithelial-mesenchymal transdifferentiation of renal tubular epithelial cells from diabetic rats.

Wu G, Tu Y, Jia R.

Biomed Pharmacother. 2010 Feb;64(2):124-9. doi: 10.1016/j.biopha.2009.06.001. Epub 2009 Oct 23.

PMID:
20006464
18.

Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats.

Li F, Xia W, Li A, Zhao C, Sun R.

Pharmacol Res. 2007 Jan;55(1):64-71. Epub 2006 Nov 1.

PMID:
17127075
19.

ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion.

Li H, Peng W, Jian W, Li Y, Li Q, Li W, Xu Y.

Cardiovasc Diabetol. 2012 Jun 13;11:65. doi: 10.1186/1475-2840-11-65.

20.

Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats.

Ho TJ, Huang CC, Huang CY, Lin WT.

Eur J Appl Physiol. 2012 Aug;112(8):2943-55. doi: 10.1007/s00421-011-2270-z. Epub 2011 Dec 9.

PMID:
22160250

Supplemental Content

Support Center